Peripheral Vascular Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peripheral Vascular Devices Market Trends and Insights

Rapid Rise in Peripheral Artery & Venous Disease Prevalence

Medicare claims showed a 19% jump in lower-extremity revascularizations between 2019 and 2024, even while average length of stay fell 23%, underscoring the push for faster, device-intensive therapy. Deep-vein thrombosis incidence across OECD members increased 8% annually over 2020-2025, fueled by post-COVID sequelae and obesity. The American Heart Association positioned DVT as the third largest acute cardiovascular syndrome in its 2025 update, elevating it from a niche condition to a mainstream interventional focus.

Shift Toward Minimally-Invasive, Catheter-Based Revascularization

Open bypass volumes in the United States dropped 31% between 2015 and 2024, while percutaneous interventions rose 47%. Drug-eluting stents now deliver 78% 5-year patency in femoropopliteal disease, neutralizing the historic durability edge of surgery. Japan’s 2024 reimbursement decision on atherectomy prompted a 40% spike in procedure counts the next quarter.

Rapid Adoption of Drug-Coated Balloon Technology

Drug-coated balloons (DCBs) captured 29% of global angioplasty-balloon income in 2025. The COMPARE trial reported 83% 12-month patency with paclitaxel balloons versus 68% for uncoated options. Safety dialog continues: the FDA ordered 5-year surveillance studies and expanded mortality warnings in 2024, tempering U.S. growth but accelerating European interest in sirolimus-based alternatives.

Growth of Office-Based Labs in OECD Nations

OBLs handled 22% of U.S. peripheral interventions in 2025, translating to USD 2.1 billion in device sales at 35% lower facility cost relative to hospital outpatient departments. Germany and Australia widened OBL-eligible code lists in 2024-2025, propelling volume out of inpatient settings.

Device Reimbursement Cuts in the US & Select EU Markets

The 2026 CMS bundled-payment ceiling of USD 18,500 per 90-day PAD episode forces hospitals to secure 15-25% device discounts. Germany trimmed lower-extremity DRG weights 8% in 2025; United Kingdom guidance now limits first-line DCB use to in-stent restenosis, curbing premium-technology uptake.

Safety Concerns Over Paclitaxel-Eluting Peripherals

FDA-mandated labeling revisions in 2024 follow a meta-analysis showing a 1.4% absolute mortality rise at five years. Japan’s PMDA paused new paclitaxel clearances pending local registry data, while EU regulators require annual imaging but have stopped short of withdrawal^{[1]FDA, “Update on Treatment of Peripheral Arterial Disease With Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents,” fda.gov}.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Atherectomy Drives Premium Shift

Atherectomy revenue is expected to post an 8.22% CAGR between 2026-2031, the highest among device classes. The peripheral vascular devices market share for angioplasty balloons was 35.18% in 2025, but aggressive price competition from Asian generics cut average selling prices 12% compared with 2022. The peripheral vascular devices market size for atherectomy systems is projected to reach a significant revenue by 2031, alongside the calcium-heavy lesion mix and supportive coding in Japan and Australia. Directional atherectomy plus DCB achieved 81% 18-month patency in calcified vessels per the DEFINITIVE LE data set. Hospitals, however, cap usage to imaging-confirmed severe calcification because a single catheter still costs USD 2,500-3,500.

Second-tier products illustrate polarization. Thrombectomy adoption surged after FDA clearance of aspiration systems for iliofemoral DVT in 2024. Self-expanding stents edge toward commoditization, with vendors pivoting to fracture-resistant alloys and thinner strut profiles. IVC filters have declined after updated ACCP guidelines against prophylactic use, whereas guidewires and sheaths anchor low-margin but indispensable recurring revenue streams.

By Clinical Application: DVT Gains as PAD Matures

Peripheral arterial disease retained 45.21% revenue in 2025; nonetheless, deep-vein thrombosis procedures are forecast to grow 5.65% annually through 2031. The peripheral vascular devices market size for DVT interventions is set to expand as catheter-directed thrombectomy earns a Class IIa recommendation in the 2024 CHEST guideline^{[2]CHEST, “Antithrombotic Therapy for VTE Disease Guideline 2024,” chestnet.org} . Hospitals devote roughly 2.8 times more device spend treating Rutherford 5-6 critical-limb ischemia than claudication cases because multilevel lesions often require adjunct atherectomy and provisional stenting. Pelvic-venous-disorder work gains from dedicated stent launches, whereas acute limb ischemia volumes inch down under better systemic anticoagulation.

Cost-effectiveness remains under scrutiny. A 2025 JAMA Network Open analysis pegged catheter-directed thrombolysis at USD 12,000 per quality-adjusted life year above oral therapy, near payer thresholds. Vendors bankroll real-world registries to prove savings from avoided post-thrombotic syndrome, aiming to entrench the procedure.

By End User: ASCs Reshape Purchasing Dynamics

Hospitals controlled 60.32% of 2025 turnover, yet ambulatory surgical centers clock a 7.12% CAGR for 2026-2031—the fastest across settings. The peripheral vascular devices market share of hospitals will dip by 2031 as CMS and private payers enlarge ASC-covered code lists. Group-purchasing leverage lets ASCs pay 23% less than hospitals for comparable devices. Vendors answer with ASC-labeled SKUs that strip accessory kits and adopt consignment or per-case pricing. OBLs, a clinic subset, already capture 22% of U.S. peripheral procedures but face possible slowdowns where state boards propose tighter oversight.

Hospitals maintain dominance in complex, high-acuity cases requiring hybrid open and endovascular techniques as well as immediate surgical backup. That bifurcation steers routine femoropopliteal angioplasty to ASCs yet keeps multilevel critical-limb work inside tertiary centers.

Geography Analysis

North America provided 42.25% of 2025 revenue. The United States braces for tempered growth as payment caps and site-of-care migration drive negotiations that pull average device spend per case down to USD 1,800 in ASCs versus USD 2,400 in hospitals. Canada invested in cath-lab capacity, yet provincial wait times of 12 weeks restrain volume. Mexico’s private-hospital tier moves ahead with lithotripsy and limus balloons, contrasting with resource-limited public institutions.

Asia-Pacific is on track for a 7.68% CAGR. China’s peripheral vascular devices market benefits from domestic champions capturing significant market share through aggressive pricing. India’s Pradhan Mantri Swasthya Suraksha Yojana accelerates cath-lab installations beyond tier-1 metros, narrowing care disparities. Japan’s aging diabetogenic population fuels PAD prevalence, though device spend per case averages USD 1,600 amid shorter hospital stays. Australia’s 2025 OBL item numbers position it as a proving ground for next-wave sirolimus balloons.

Europe contributes sizeable absolute dollars, yet heterogenous reimbursement rules split adoption curves. Germany reimburses DCBs as first-line therapy, while the United Kingdom caps DCBs for restenosis. France green-lit orbital atherectomy in 2024. Eastern Europe, reliant on earlier-generation balloons, receives EU structural funds earmarked for cath-lab upgrades that will underpin gradual technology catch-up.

Regulatory Landscape

Regulatory scrutiny for peripheral vascular devices is tightening around clinical evidence, post-market surveillance, and pathway-specific documentation across major markets. In the United States, FDA guidance and special controls for peripheral percutaneous transluminal angioplasty (PTA) and specialty catheters, atherectomy devices, embolization devices, and vascular prostheses shape 510(k) expectations, while continued safety scrutiny of paclitaxel-coated peripheral devices keeps longer-term follow-up and labeling alignment central.

In Europe, the EU MDR environment remains documentation-intensive, but March 2026 European Commission delegated regulations (C(2026) 1798 and C(2026) 1809) expanded the Well-Established Technology (WET) list, creating targeted relief for certain well-established cardiovascular devices such as peripheral catheters and guidewires by reducing clinical investigation and technical documentation assessment burdens. In China, the NMPA and CMDE increased specificity in 2026, including April 2026 IVUS diagnostic-device registration review guidance that separates peripheral and coronary registration units, and 2026 medical-device guideline revisions plan spanning hundreds of Class II and Class III categories, reinforcing the need for device-specific dossiers and locally aligned clinical evidence.

Market Opportunities and Future Outlook

White-space is widening in deep venous and below-the-ankle disease, where dedicated devices and reimbursement mechanisms are becoming more defined. In January 2026, FDA approval of W. L. Gore & Associates GORE VIABAHN FORTEGRA Venous Stent for IVC, iliac, and iliofemoral indications broadened the addressable device set for deep venous disease and supports wider standardization of venous stenting pathways beyond off-label use. At the same time, January 2026 dedicated CPT codes for inframalleolar procedures created a clearer reimbursement route for pedal revascularization, which aligns with rising focus on chronic limb-threatening ischemia (CLTI) workflows across ASCs, OBLs, and hospital outpatient settings.

Evidence development is also shifting toward approaches that preserve future treatment options, address calcified anatomy, and respond to drug-coating safety debates. The 2025 FDA De Novo clearance for Reflow Medicals Spur Peripheral Retrievable Stent System for infrapopliteal disease, along with 2026 trial updates (including DEEPER REVEAL 12-month results and peer-reviewed pedal-intervention outcomes for Cagent Vasculars Serranator serration balloon), points to a pipeline of reversible or vessel-preparation tools aimed at limb salvage endpoints rather than single-procedure success. Drug-coated balloon innovation is moving into sirolimus platforms as well, supported by 2026 randomized SirPAD results presented by Concept Medical for its MagicTouch PTA sirolimus-coated balloon versus uncoated angioplasty, which offers a commercialization and tendering lever in markets where paclitaxel labeling and surveillance requirements constrain adoption.